Loading stock data…
BTMD
$2.21-0.13 (-5.56%)
Market ClosedLast close Jun 9
biote Corp.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
biote Corp. in the Healthcare sector is trading at $2.21. Wall Street consensus targets $2.99 (5 analysts), implying a +35.1% move over the next 12 months. The stock is currently 53% below its 52-week high of $4.75, remaining 8.7% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +35.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$2.21
Potential Downside
0%
Whystock Fair Value$2.21
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormona...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-27.82%
Volume
Today's trading volume
482,779
Recent News
How The Evolving Story For biote (BTMD) May Shape Future Investor Expectations
The latest analyst update for biote keeps the existing price targets unchanged, signaling no revisions to where the stock is currently pegged by coverage. Even without new target moves, the story around biote does not stand still, and investors still have information to track. Ahead, you will see how to monitor shifts in the narrative so you can stay on top of what matters as new data and opinions emerge. Analyst Price Targets don't always capture the full story. Head over to our Company...
biote Corp. Q1 2026 Earnings Call Summary
Moby summary of biote Corp.'s Q1 2026 earnings call
biote Q1 Earnings Call Highlights
biote (NASDAQ:BTMD) executives said a voluntary recall of certain bioidentical hormone pellet inventory created a temporary but meaningful headwind in the company’s first quarter of 2026, impacting procedure revenue, margins, and salesforce productivity while management works to restore supply conti
biote Corp. (BTMD) Q1 Earnings and Revenues Lag Estimates
biote Corp. (BTMD) delivered earnings and revenue surprises of -33.33% and -2.71%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
How The biote (BTMD) Narrative Is Shifting As Targets Tighten And Guidance Holds
Biote’s fair value estimate has been trimmed from US$3.17 to US$2.97 per share, signaling a tighter view on what analysts currently think the stock is worth. That change lines up with recent commentary, where many analysts are lowering price targets into a US$2 to US$3 range while balancing recall related challenges against progress on sales execution and clinic growth efforts. Read on to see how these shifting targets fit into the broader biote story and what to watch as the narrative...